PFIZER INC Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months
PFIZER INC (PFE) had Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months of $417.00 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases › Lessee, Operating Lease, Liability, to be Paid, Rolling Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths · last filed 2026-02-26
- 2025-12-31: Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months $417.00M.
- 2024-12-31: Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months $443.00M.
- 2023-12-31: Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months $639.00M.
- 2022-12-31: Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months $662.00M.
| Period end | Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months |
|---|---|
| 2025-12-31 | $417.00M 10-K · filed 2026-02-26 |
| 2024-12-31 | $443.00M 10-K · filed 2025-02-27 |
| 2023-12-31 | $639.00M 10-K · filed 2024-02-22 |
| 2022-12-31 | $662.00M 10-K · filed 2023-02-23 |
| 2021-12-31 | $520.00M 10-K · filed 2022-02-24 |
| 2020-12-31 | $357.00M 10-K · filed 2021-02-25 |
| 2019-12-31 | $323.00M 10-K · filed 2020-02-27 |
| 2019-09-29 | $322.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $302.00M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $287.00M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |